Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
- Phase I exposure screening and trigger evaluation.
- Environmental fate and ecotoxicity review, with Phase II work where required.
- PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
- Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
